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Abstract:  Spiders  are  the  most  successful  venomous  animals  and  the  most  abundant 
terrestrial  predators.  Their  remarkable  success  is  due  in  large  part  to  their  ingenious 
exploitation of silk and the evolution of pharmacologically complex venoms that ensure 
rapid subjugation of prey. Most spider venoms are dominated by disulfide-rich peptides 
that typically have high affinity and specificity for particular subtypes of ion channels and 
receptors. Spider venoms are conservatively predicted to  contain more than 10 million 
bioactive peptides, making them a valuable resource for drug discovery. Here we review 
the structure and pharmacology of spider-venom peptides that are being used as leads for 
the  development  of  therapeutics  against  a  wide  range  of  pathophysiological  conditions 
including cardiovascular disorders, chronic pain, inflammation, and erectile dysfunction. 
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1. Introduction: The Diverse Pharmacology of Spider Venoms 
Spiders are the most successful venomous animals with an estimated 100,000 extant species [1]. 
The vast majority of spiders employ a lethal cocktail to rapidly subdue their prey, which are often many 
times their own size. However, despite their fearsome reputation, less than a handful of these insect 
assassins are harmful to humans [2,3]. Nevertheless, it is this small group of medically important 
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species that first prompted scientists more than half a century ago to begin exploring the remarkable 
pharmacological diversity of spider venoms. 
Amongst the ranks of animals that employ venom for their survival, spiders are the most successful, 
the most geographically widespread, and arguably consume the most diverse range of prey. Although 
the predominant items on a spider’s dinner menu are other arthropods, larger species will readily kill 
and feed on small fish, reptiles, amphibians, birds, and mammals. Thus, spider venoms contain a 
wealth of toxins that target a diverse range of receptors, channels, and enzymes in a wide range of 
vertebrate and invertebrate species. 
Spider venoms are complex cocktails composed of a variety of compounds, including salts, small 
organic molecules, peptides, and proteins [4–9]. However, peptides are the primary components of 
spider venoms, and some species produce venom containing >1000 unique peptides of mass 2–8 kDa 
[10]. Based on the number of described spider species and a relatively conservative estimate of the 
complexity of their venom it has been estimated that the potential number of unique spider venom 
peptides could be upwards of 12 million [11]. In recent years there has been an exponential increase in 
the number of spider-toxin sequences being reported [12] due to the application of high-throughput 
proteomic  [13,14]  and  transcriptomic  [15–17]  approaches,  or  a  combination  of  these  
methods  [10,18,19].  In  the  last  18  months  alone  the  number  of  toxins  in  the  ArachnoServer  
spider-toxin  database  [20,21]  has  more  than  doubled,  and  is  now  excess  of  900  (see 
http://www.arachnoserver.org/). Nevertheless, our knowledge of the diversity of spider-venom peptides 
is still rudimentary, with less than 0.01% of potential peptides having been isolated and studied. 
Although  only  a  small  number  of  spider  venom  peptides  have  been  pharmacologically 
characterized, the array of known biological activities is impressive [9]. In addition to the well known 
neurotoxic  effects  of  spider  venoms,  they  contain  peptides  with  antiarrhythmic,  antimicrobial, 
analgesic, antiparasitic, cytolytic, haemolytic, and enzyme inhibitory activity. Furthermore, the crude 
venom of Macrothele raveni has antitumor activity, for which the responsible component has not yet 
been identified [22,23]. Finally, larger toxins such as the latrotoxins from the infamous black widow 
spider (Latrodectus mactans) and related species induce neurotransmitter release and they have played 
an important role in dissecting the process of synaptic vesicle exocytosis [24]. 
Since spiders employ their venom primarily to paralyse prey, it is no surprise that these venoms 
contain an abundance of peptides that modulate the activity of neuronal ion channels and receptors. 
Indeed, the majority of characterized spider-venom peptides target voltage-gated potassium (KV) [25], 
calcium (CaV) [26,27], or sodium (NaV) [26,28] channels. More recently, novel spider-venom peptides 
have been found that interact with ligand-gated channels (e.g., purinergic receptors [29]) and recently 
discovered families of channels such as acid sensing ion channels [30], mechanosensitive channels 
[31], and transient receptor potential channels [32]. Not only do most of these peptides have selectivity 
for a given class of ion channel, they can have anything from mild preference to exquisite selectivity 
for a given channel subtype. This potential for high target affinity and selectivity makes spider-venom 
peptides an ideal natural source for the discovery of novel therapeutic leads [33]. 
Despite the advent of automation and the rise of high-throughput and high-content screening in the 
pharmaceutical industry there has been a sharp decline in the rate of discovery and development of 
novel  chemical  entities  [34,35].  We  recently  reviewed  the  emerging  role  that  venom-derived Toxins 2010, 2                         
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components can play in addressing this decline with an emphasis on technical advances that can aid the 
discovery  process  [36].  It  is  worth  noting that, as  of 2008, two of the 20 FDA-approved peptide 
pharmaceuticals were derived from animal venoms (i.e., ziconitide and exendin-4) [37]. In this review 
we specifically examine the structure, targets, and mechanisms of action of spider-venom peptides with 
potential therapeutic applications. 
2. Peptide Nomenclature 
All peptide names are based on the rational nomenclature for naming peptide toxins that has been 
adopted by ArachnoServer and UniProtKB [12]. Common synonyms are also provided. 
3. The Magical Properties of the Inhibitor Cystine Knot 
Peptides have generally been considered poor candidates for human therapeutics because of their 
susceptibility  to  proteolytic  degradation  in  vivo  and  their  limited  penetration  of  intestinal  mucosa 
[37,38]. However, in contrast with most peptides, the presence of an inhibitor cystine knot (ICK) in 
most spider-venom toxins provides these peptides with extraordinary stability. The inhibitor cystine 
knot (ICK) is defined as an antiparallel  sheet stabilized by a cystine knot [39–41]. In spider toxins, 
the  sheet typically comprises only two  strands although a third N-terminal strand is sometimes 
present  (Figure  1A)  [42].  The  cystine  knot  comprises  a  ring  formed  by  two  disulfides  and  the 
intervening  sections  of  polypeptide  backbone,  with  a  third  disulfide  piercing  the  ring  to  create  a 
pseudo-knot (Figure 1B). The compact hydrophobic core of the ICK motif consists primarily of the two 
central disulfide bridges that emanate from the two   strands that characterize the ICK fold [43]. 
Except for the special case of cyclic ICK peptides, cystine knots are not true knots in the mathematical 
sense as they can be untied by a non-bond-breaking geometrical transformation [44]. Nevertheless, the 
cystine knot converts ICK toxins into hyperstable mini-proteins with tremendous chemical, thermal, 
and biological stability. ICK toxins are typically resistant to extremes of pH, organic solvents, and high 
temperatures [45]. However, from a therapeutic perspective, their most important property is their 
resistance to proteases; ICK peptides are typically stable in human serum for several days and have 
half-lives in simulated gastric fluid [46] of >12 hours (GFK and VH, unpublished). It was recently 
demonstrated that stabilization of a 16-residue -conotoxin through cyclization dramatically increased 
its oral activity [47], and it is therefore possible that the inherent stability of ICK peptides might impart 
them with oral activity without the need to introduce exotic modifications. 
ICK toxins have proliferated in spider venoms to the point where they now dominate most spider-
venom  peptidomes.  The  marked  insensitivity  of  this  structural  scaffold  to  changes  in  intercystine 
residues has enabled spiders to develop diverse pharmacologies using the same disulfide framework 
[48]. Moreover, many of these ICK peptides not only have high affinity but also exquisite selectivity 
for their cognate targets. With the exception of those with antibacterial/antifungal activity, all of the 
spider-venom peptides to be discussed in this review contain an ICK motif. Toxins 2010, 2                         
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Figure 1. (A) The inhibitor cystine knot (ICK) motif comprises an antiparallel  sheet 
stabilized by a cystine knot.  strands are shown in orange and the six cysteine residues that 
form the cystine knot are labeled 1–6. In spider toxins, the  sheet typically comprises only 
the two  strands housing cysteine residues 5 and 6, although a third N-terminal strand 
encompassing cysteine 2 is sometimes present. The two ―outer‖ disulfide bonds are shown 
in green and the ―inner‖ disulfide bridge is red. (B) The cystine knot of the 37-residue 
spider-venom peptide -hexatoxin-Hv1a [43]. The cystine knot comprises a ring formed by 
two disulfides (green) and the intervening sections of polypeptide backbone (gray), with a 
third disulfide (red) piercing the ring to create a pseudo-knot. The hydrophobic core of the 
toxin consists primarily of the two central disulfide bridges connected to the  strands. Key 
functional residues in ICK toxins are often located in the  hairpin that projects from the 
central disulfide-rich core of the peptide. 
 
4. No Pain, Much Gain: Spider Toxins with Analgesic Potential 
Normal nociceptive pain is a key adaptive response that limits our exposure to potentially damaging 
or life-threatening events. In contrast, aberrant long-lasting pain transforms this adaptive response into 
a debilitating and often poorly managed disease. About 20% of adults suffer from chronic pain, a 
figure that increases to 50% for those older than 65 [49]. In 2007, global sales of pain medications 
totaled $34 billion [50], highlighting the pervasive nature of this condition. Nevertheless, there are few 
drugs available for treatment of chronic pain, and many of these have limited efficacy and significant 
side-effects.  Recently,  a  number  of  ion  channels  have  been  shown  to  be  critical  players  in  the 
pathophysiology of pain, and in many cases the most potent and selective blockers of these channels 
are spider-venom peptides. Here we review some of these peptides with promise as drug leads or as 
analgesics in their own right. 
2.1. Modulators of Acid Sensing Ion Channels 
Acid sensing ion channels (ASICs) are proton-gated sodium channels that open in response to low 
pH. They belong to the epithelial sodium channel/degenerin (ENaC/DEG) superfamily of ion channels Toxins 2010, 2                         
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which have the same overall topology and selectivity for transporting sodium [51]. However, ASICs 
are distinguished by their restriction to chordates, their predominantly neuronal distribution, and their 
activation by decreases in extracellular pH [52,53]. To date, seven ASIC subunits have been identified: 
ASIC1a,  ASIC1b,  and  ASIC1b2  (splice  isoforms  from  the  ASIC1  gene),  ASIC2a  and  ASIC2b  
(splice isoforms of the ASIC2 gene), ASIC3 and ASIC4. Functional ASIC channels comprise either 
homomeric or heteromeric trimers of these subunits. ASIC2b and ASIC4 are insensitive to protons and 
do  not  form  homomeric  channels,  but  rather  are  incorporated  into  heteromeric  channels  and  may 
modify the kinetics of channel  activation and inactivation. The different combinations of subunits 
allow the different trimeric channels to sense a wide range of extracellular pH changes. 
ASIC1a is the most abundant ASIC subunit in the central nervous system (CNS) and it has the highest 
affinity  for  protons  [53].  It  has  been  implicated  as  a  novel  therapeutic  target  for  a  broad  range  of 
pathophysiological  conditions  including  pain,  ischemic  stroke,  depression,  and  autoimmune  and 
neurodegenerative diseases such as multiple sclerosis, Huntington’s Disease, and Parkinson’s Disease 
[53–56]. Inhibitors of ASIC1a might therefore be therapeutically valuable for some of these conditions. 
The only potent and specific inhibitor of ASIC1a that has been identified to date is -theraphotoxin-Pc1a 
(-TRTX-Pc1a; also known as psalmotoxin-1 (PcTx1)), a 40-residue ICK peptide isolated from the 
venom of the Trinidad chevron tarantula Psalmopoeus cambridgei. -TRTX-Pc1a inhibits homomeric 
ASIC1a channels, but not other ASIC subtypes, with an IC50 of 0.9 nM [30]. -TRTX-Pc1a was shown 
to be an effective analgesic, comparable to morphine, in rat models of acute pain [57] and peripheral 
administration of this peptide resulted in neuroprotection in a mouse model of ischemic stroke even 
when administered hours after injury [58]. 
-TRTX-Pc1a  is  only  effective  when  administered  intrathecally  or  by  intracerebroventricular 
injection [57]. Thus, native -TRTX-Pc1a is unlikely to be a clinically useful analgesic except in the 
most chronic pain sufferers as intrathecal administration is an invasive method of drug delivery with 
inherent risks [59]. As for Prialt®, a peptide from cone snail venom that was recently approved for the 
treatment of chronic pain [60], intrathecal -TRTX-Pc1a use would likely be limited to management of 
severe chronic pain in patients who are intolerant or refractory to other treatments. Thus, there is much 
interest in developing mimetics of -TRTX-Pc1a that might be orally active or at least deliverable via 
subcutaneous  or  intramuscular  injection.  Thus,  several  attempts  have  been  made  to  model  the  
-TRTX-Pc1a:ASIC1a interaction [61,62] with a view to providing a template that can be used for in 
silico screening and/or rational design to develop small-molecule mimetics of -TRTX-Pc1a. Thus, 
even in cases where a spider-venom peptide itself may not be a viable therapeutic, it can still be an 
invaluable tool for target validation and for providing a pharmacophore for rational drug design. 
2.2. Modulators of Voltage-Gated Sodium Channels 
Voltage-gated sodium (NaV) channels provide a current pathway for the rapid depolarization of 
excitable cells that is required to initiate an action potential. Functional channels are composed of a 
pore forming  subunit whose gating and kinetics is modified via association with one of four  
subunits. The  subunits are classified into nine different subtypes, denoted NaV1.1 to NaV1.9 [63], and 
they are further characterized by their sensitivity to tetrodotoxin (TTX). NaV1.5, NaV1.8 and NaV1.9 
are TTX-resistant whereas all other subtypes are TTX-sensitive. Toxins 2010, 2                         
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Of the nine NaV  subtypes,  NaV1.3, NaV1.7, and  NaV1.8 are involved in pain signaling [64,65]. 
However, in recent years, NaV1.7 has emerged as perhaps the best validated pain target based on 
several  remarkable human genetic studies.  Gain-of-function mutations  in  the gene encoding the   
subunit of NaV1.7 (SCN9A) underlie two painful neuropathies known as paroxysmal extreme pain 
disorder  (PEPD)  and  inherited  erythromelalgia  (IE)  [66,67],  whereas  loss-of-function mutations  in 
SCN9A result in a congenital indifference to all forms of pain [68,69]. Remarkably, apart from their 
complete inability to sense pain, partial loss of smell (hyposmia) is the only other sensory impairment 
in individuals with this channelopathy [70]; they have no motor or autonomic dysfunction, with normal 
blood pressure and temperature regulation. NaV1.7 is located at the terminal of sensory neurons, where 
it is ideally positioned to serve its proposed role as a threshold channel that amplifies pain signals 
transmitted above a certain level [71]. 
The preferential expression of NaV1.7 in peripheral sensory and sympathetic neurons makes it an 
ideal target for novel analgesics. Indeed, it is probable that the known analgesic effects of a number of 
nonspecific NaV channel blockers such as the local anaesthetic lidocaine, tricyclic antidepressants such 
as amitriptyline, and anticonvulsants such as carbamezepine are at least in part mediated through their 
effects on NaV1.7. However, the nonspecific block of NaV channels by these drugs means that they are 
only efficacious at or near toxic levels, with numerous CNS-related side-effects such as dizziness and 
ataxia [64]. Thus, subtype-specific blockers of NaV1.7 are likely to be useful drugs for treatment of 
chronic pain as well as inherited neuropathies such as IE and PEPD [64,65,71]. Recent studies have 
revealed that spider venoms may provide an excellent source of such subtype-specific blockers. 
Modulation of NaV channels is a dominant pharmacology in spider venoms [72], indicating that 
spiders long ago evolved the capacity to block NaV channels as a mechanism for killing insect prey. 
Since the insect NaV channel shares 55–60% identity with each of the vertebrate NaV subtypes [28] it is 
perhaps not surprising that numerous spider toxins have been isolated with activity against vertebrate 
NaV channels. However, according to ArachnoServer [20,21], only three peptide toxins have been 
isolated thus far with activity against vertebrate NaV1.7 channel, and only six toxins in total have been 
isolated with submicromolar potency against NaV1.3, NaV1.7, or NaV1.8 (Table 1). All of these toxins 
were isolated from members of the Theraphosidae family (commonly known as tarantulas). 
Table 1. Spider-venom peptides with submicromolar potency against NaV1.3, NaV1.7, or NaV1.8
1. 
Toxin Name 
No. of 
Residues 
ICK 
Scaffold 
IC50 (nM) against Various NaV Subtypes 
1.1  1.2  1.3  1.4  1.5  1.6  1.7  1.8 
β-TRTX-Tp1a  35  Yes  NA
2  NA  NA  NA  NA  NA  51  27
3 
β-TRTX-Tp2a  30  Yes  NA  41  102  NA  79  26  0.3  146 
β-TRTX-Ps1a  34  Yes  610  0.6  42  288  72  NA  NA  >1000 
β-TRTX-Cm1a  33  Yes  523  3  NA  888  323  NA  NA  >1000 
β-TRTX-Cm1b  33  Yes  407  8  88  400  1634  NA  NA  >2000 
-TRTX-Cj1a
4  33  Yes  NA  NA  NA  NA  32  130  130  NA 
1. Data extracted from ArachnoServer (http://www.arachnoserver.org) on 01/11/10; 2. NA indicates data not 
available; 3.The NaV subtype against which a toxin is most active is highlighted in gray; 4. This toxin does not 
block the channel but rather delays its inactivation. Toxins 2010, 2                         
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The  most  potent  known  blocker  of  human  NaV1.7,  with  an  IC50  of  0.3  nM,  is  β-TRTX-Tp2a 
(Protoxin  II),  a  30-residue  ICK  peptide  isolated  from  the  venom  of  the  Green  velvet  tarantula 
Thrixopelma pruriens. This toxin has a 100-fold selectivity for human NaV1.7 compared with NaV1.2, 
NaV1.3,  NaV1.5,  NaV1.6  and  NaV1.8  [73,74].  Nevertheless,  β-TRTX-Tp2a  still  has  relatively  high 
potency against NaV1.2 (IC50 = 41 nM) and NaV1.5 (IC50 = 79 nM) and consequently it is lethal to rats 
when injected intravenously at 1.0 mg/kg or by intrathecal administration at 0.1 mg/kg. In contrast, 
intrathecal  administration  of  β-TRTX-Gr1b,  a  related  toxin  from  the  venom  of  the  Chilean  rose 
tarantula Grammostola rosea that is 89% identical to β-TRTX-Tp2a, induced analgesia in a variety of 
rat pain models without any confounding side-effects, and the peptide did not exhibit cross tolerance 
with morphine [75]. It is therefore likely that the NaV subtype selectivity of β-TRTX-Gr1b, which 
remains  to  be determined, is  very different to that of β-TRTX-Tp2a. Structure-function studies of 
closely related spider-venom peptides with different NaV selectivity profiles, such as β-TRTX-Tp2a 
and β-TRTX-Gr1b, should provide structure-activity relationships that can be used to rationally design 
selective blockers of NaV1.7 with therapeutic potential as novel analgesics. 
2.3. Modulators of P2X Receptors 
P2X purinergic receptors are ATP-gated non-selective ion channels permeable to Na
+, K
+ and Ca
2+ 
[76]. Currently, seven subunits (P2X1-7) are known [77] and functional P2X channels are formed by 
association of these subunits to form homomeric or heteromeric trimers [78]. To date, six different 
heteromeric channels with unique pharmacological properties have been discovered [77]. Of these, 
P2X3 [79], P2X4 [80], and P2X7 [77] are involved in a range of pain states. Several antagonists of these 
receptors have been patented and some P2X7 antagonists have already entered Phase I and II clinical 
trials [81]. 
P2X3 is the best-studied subtype with regards to pain. Consistent with its localization on ascending 
nociceptive sensory neurons [79], it has been found to be involved in acute pain, inflammatory pain, 
chronic  neuropathic  pain,  visceral  pain,  migraine  pain,  and  cancer  pain  [79,82].  Very  few  
subtype-specific antagonists of P2X3 are known [83–85]. Recently, however, a potent and selective 
modulator of P2X3 was isolated from the venom of the central Asian spider Geolycosa sp. and named 
purotoxin-1 (PT1) [29]. PT1 is a 35-residue peptide with four disulfide bonds, three of which form an 
ICK motif. It has a complex pharmacology that leads to a concentration-dependent prolongation of 
channel desensitization, with an IC50 of ~12 nM [29]. 
The analgesic potential of PT1 was measured in rat models of acute and chronic inflammatory pain 
in  which  hind  paw  withdrawal  latency  was  measured  after  induction  of  thermal  hyperalgesia  by 
injection  of  either  carrageenan  or  Freund’s  complete  adjuvant, respectively.  PT1 exhibited similar 
analgesic effects as the P2X3 antagonist A-317491, but the amount of PT1 required was three orders of 
magnitude lower [29]. PT1 was also effective in reducing the number of nocifensive events triggered 
by the injection of capsaicin or formalin [29]. Thus, PT1 appears to be a promising lead compound for 
the development of analgesics that target P2X3 receptors. PT1 is the first P2X modulator isolated from 
spider venoms and therefore it will be interesting in future studies to examine how widespread this 
pharmacology is in the venoms of these animals. Toxins 2010, 2                         
 
 
2858 
2.4 Spider-Venom Peptides that Modulate Other Pain Targets 
In  addition  to  the  molecular  targets  discussed  above,  there  are  several  other  ion  channels  and 
receptors that have either been validated or are being actively investigated as analgesic targets. For 
example, Ziconitide (Prialt®), an analgesic peptide derived from cone snail venom, targets CaV2.2 
channels  [86],  while  another  cone  snail  peptide  that  targets  the norepinephrine transporter [87]  is 
currently in Phase II clinical trials for the treatment of post-operative pain. Several transient receptor 
potential (TRP) channels including TRPV1, TRPV4, TRPA1, and TRPM8 are also being investigated 
as analgesic targets and a number of TRPV1 antagonists are in clinical trials [88,89]. Spider venoms 
represent a potential source of modulators for all of these drug targets. For example, block of CaV 
channels is a dominant pharmacology in spider venoms [72]; more than 65 blockers of vertebrate CaV 
channels are currently listed in the ArachnoServer database, of which 17 are active on CaV2.2. In 
addition, several spider-venom peptides have been isolated that modulate that activity of TRPV1 [32]. 
However,  very  few studies  have explored whether spider-venom  peptides  are capable of targeting 
ligand-gated receptors, G-protein coupled receptors, or neurotransmitter transporters, and this is likely 
to be a fruitful line of enquiry for future research. 
5. Antiarrhythmic Drugs from Spider Venoms 
Mechanosensitive channels (MSCs), sometimes referred to as stretch-activated channels, are found 
in all cells [90], but mechanosensitivity is best viewed as a phenotype rather than a genotype [91]. Only 
two  selective  inhibitors  of  MSCs  have  been  isolated,  namely  M-TRTX-Gr1a  (GsMTx4)  and  
-TRTX-Gr2a  from  the  venom  of  the  tarantula  Grammostola  rosea  [92,93];  the  latter  peptide  is 
identical  to  κ-TRTX-Ps1b  (Phrixotoxin-2)  isolated  from  venom  of  the  Chilean  copper  tarantula 
Paraphysa scrofa. -TRTX-Gr2a/κ-TRTX-Ps1b is a low affinity blocker of MSCs, with a Kd of 6 M 
in rat astrocytes, but it potently inhibits KV4.2 and KV4.3 channels, with IC50 values of 34 and 71 nM, 
respectively. In contrast, M-TRTX-Gr1a is a significantly more potent inhibitor of MSCs, with a Kd of 
630 nM in rat astrocytes [92], and it has proved to be a valuable tool for study of MSCs [31]. 
Atrial fibrillation results from stretching of the atrial chamber, which has been associated with the 
activity of mechanosensitive channels. Block of these channels presumably explains the remarkable 
observation  that  M-TRTX-Gr1a  suppresses  atrial  fibrillation  in  dilatated  rabbit  heart  [94].  This 
suggests that MSCs might be a novel target for antiarrhythmic agents. M-TRTX-Gr1a itself is unlikely 
to be a useful therapeutic agent because of its unusual mode of action. It does not interact directly with 
MSCs, since an enantiomer comprised entirely of D-amino acids is equipotent with the native peptide 
[31].  Rather, the peptide perturbs the channel-bilayer boundary by partitioning into the membrane 
[95,96],  and  this  membrane-disrupting  activity  presumably  also  underlies its  antimicrobial  activity 
[97]. Nevertheless, M-TRTX-Gr1a is likely to be a useful tool for determining the potential of MSCs 
as a therapeutic target for the treatment of pathologies as diverse as cardiac arrhythmias, spinal cord 
damage, muscular dystrophy, and gliomas [31]. Toxins 2010, 2                         
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6. Spider Toxins for Treating Erectile Dysfunction 
Penile  erection  is  a  complex  process  initiated  by  activation  of  parasympathetic  pelvic  nerves, 
resulting in arterial dilatation followed by relaxation of corpora cavernosa [98]. Nitric oxide (NO) 
plays a major role in the generation and maintenance of intracavernous pressure and penile erection 
[99]. NO, which is released from nitrergic nerves within the trabecular and arterial tissues as well as by 
the endothelial tissue of penile arteries, exerts its relaxing action by activating soluble guanylyl cyclase. 
This causes an increase in intracellular cGMP which relaxes the smooth muscles of the cavernous body 
and results in penile erection. 
There are several drugs on the market today for treatment of erectile dysfuncion (ED), including 
sildenafil  (Viagra®),  tadalafil  (Cialis®),  and  vardenafil  (Levitra®)  [100].  These  drugs  all  affect 
phosphodiesterase type 5 (PDE5), which is present in large amounts in the penis. Inhibition of PDE5 
leads  to  increased  levels  of  cGMP  and  hence  increased  blood  flow  to  the  penis  [101].  The 
aforementioned  PDE5-blocking  drugs  have  similar  side  effects  including  headache,  flushing, 
dyspepsia, nasal congestion, impaired vision, photophobia and blurred vision [102]. Hence, there is a 
need for better drugs with fewer side effects for the treatment of ED. 
In South America, humans bitten by the ―armed-spider‖ Phoneutria nigriventer experience a variety 
of  symptoms  including  priapism.  The  toxin  responsible  for  this  effect,  -ctenitoxin-Pn2a  
(-CNTX-Pn2a; Tx2-6) was isolated in 1992 [103] and subsequently found to modulate the activity of 
NaV  channels  [104].  -CNTX-Pn2a  is  a  48-residue  toxin  with  five  disulfide  bonds;  it  is  unclear 
whether it contains an ICK motif. The toxin has a complex pharmacology that results in inhibition of 
NaV  channel  inactivation  and  a  hyperpolarizing  shift  in  the  channel  activation  potential  [104]. 
Intracerebroventricular  injection of  -CNTX-Pn2a  into mice results in scratching, hypersalivation, 
lachrymation,  sweating,  and  agitation  followed  by  spastic  paralysis  of  the  anterior  and  posterior 
extremities  and  death  [103].  However,  subcutaneous  injection  of  -CNTX-Pn2a  into  rats  induced 
erection,  and  rats  with  severely  depressed  erectile  function  could  be  normalized  by  subcutaneous 
administration of -CNTX-Pn2a [105]. A minimum dose of only 0.006 g/kg was required to cause an 
erection in mice when injected directly into the corpus cavernosum; at this dose, no local and systemic 
collateral toxic effects were observed and the erection was lost after 120–140 min [106]. 
The  potency  and  specificity  of  -CNTX-Pn2a  makes  it  an  attractive  lead  molecule  for  the 
development of new therapeutics for ED treatment that might have fewer side effects than current 
drugs. The pharmacology inherent in -CNTX-Pn2a may be widespread in spider venoms, at least 
amongst  members  of  the  Ctenidae  family  (which  currently  comprises  475  species  [107]),  since 
orthologous toxins are found in several other Phoneutria species as well as a related ctenid spider  
(see ArachnoServer entry http://www.arachnoserver.org/toxincard.html?id=16). 
7. Antibacterial and Antifungal Toxins 
The introduction of antibiotics in the 1930s and 1940s was in large part responsible for the dramatic 
decline in  the mortality rate from  communicable diseases in  developed countries [108]. However, 
bacteria are remarkably proficient at adapting to environmental stresses, and they have evolved at least 
one mechanism of resistance for all 17 classes of antibiotics that have been developed to date [109]. Toxins 2010, 2                         
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The recent widespread emergence of antibiotic resistance in clinically important bacterial pathogens 
such as Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis, combined with 
a dramatic decrease in the rate of development of new antibiotics, has led some to suggest that we may 
be  approaching  the  post-antibiotic  era  [109].  While  this  may  overstate  the  problem,  there  is 
nevertheless an urgent need to develop new antimicrobials with novel mechanisms of action. 
The recent  successful  introduction of the lipopeptide antibiotic daptomycin  [110] has rekindled 
interest in antimicrobial peptides [111]. To date, 40 membrane-acting antimicrobial peptides (MAMPs) 
have  been  isolated  from  the  venom  of  four  different  families  of  araneomorphs,  suggesting  that 
antimicrobial activity is widespread in this infraorder of spiders. These MAMPs often have a wide 
range of antimicrobial activities, with some toxins active against Gram-positive and Gram-negative 
bacteria  as  well  as  fungal  pathogens  such  as  Candida  albicans  [112].  Some  MAMPs  also  have  
anti-trypanosomal activity [113]. Curiously, no MAMPs have thus far been isolated from the venom of 
mygalomorph spiders. It is possible that MAMPs were recruited into araneomorph venoms following 
the split from mygalomorphs around 280 million years ago [114].  
MAMPs differ from most other spider-venom peptides in their structure and mode of action. Rather 
than utilizing the ICK fold common to most spider toxins, MAMPs are -helical amphipathic peptides 
that interact with and perturb cell membranes to yield their antimicrobial effects [115–118]. This mode 
of action can be potentially problematic from a therapeutic perspective since MAMPS that interact 
nonspecifically with cell membranes are cytolytic [119]. Indeed, this property is likely to be the basis 
of their biological function in spider venoms. Although it has been proposed that MAMPS might 
protect the spider’s venom apparatus against infection [115] their primary role is more likely to be as 
membrane  disrupting  agents  that augment the activity of the disulfide-rich neurotoxic peptides  by 
facilitating their spread [120,121]. 
It  has  been  shown  that  the  cytolytic  activity  of  at  least  some  spider-venom  MAMPs  can  be 
minimized  by  truncation  without  significantly  disrupting  their  antimicrobial  activity  [122]. 
Nevertheless, the therapeutic use of these peptides is likely to be limited by their inherent susceptibility 
to proteolysis, which is likely to result in short gut and plasma half-lives. Whether this problem can be 
solved  by  strategies  such  as  cyclization  or  grafting  key  sequence  elements  onto  more  stable  ICK 
scaffolds [123] remains to be seen. 
8. Antimalarial Toxins 
The antimicrobial action of spider toxins is not limited to bacteria and fungi, but also extends to the 
malaria  parasite.  There  were  243  million  cases  of  malaria  in  2008,  resulting  in  a  death  every  
35  seconds,  and  most  of  these  were  children  under  the  age  of  five  [124].  Malaria  is  caused  by 
Plasmodium infections spread by female anopheline mosquitoes. There are five genera of Plasmodium 
that cause malaria, with Plasmodium falciparum being the most virulent. Widespread resistance to 
chloroquine  has  made  this  drug  largely  ineffective  for  treating  Plasmodium falciparum  in  
high-transmission areas and few cheap alternatives are available [125]. 
U1-TRTX-Pc1a  (Psalmopeotoxin  I)  and  U2-TRTX-Pc1a  (Psalmopeotoxin  II)  are  ICK  peptides 
isolated from the venom of the Trinidad chevron tarantula Psalmopoeus cambridgei that are effective 
against the intra-erythrocyte stage of Plasmodium falciparum. Interestingly, this is the same spider Toxins 2010, 2                         
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from which -TRTX-Pc1a, the most potent known blocker of ASIC1a, was isolated, indicating that a 
single spider can provide multiple therapeutic leads. U1-TRTX-Pc1a and U2-TRTX-Pc1a are unrelated 
peptides that comprise 33 and 28 residues, respectively. They inhibit intra-erythrocyte development of 
Plasmodium falciparum with ED50 values of 1.1–1.6 M but, unlike most MAMPS, they do not have 
hemolytic, antibacterial or antifungal activity. The mode of action of these peptides is unknown. It 
seems unlikely that they directly target the malaria parasite since this would require the peptides to 
traverse  both  the  erythrocyte  membrane  as  well  as  the  parasitophorous  vacuolar  membrane  that 
encapsulates the parasite. One possibility is that these toxins target the new permeability pathways that 
are established in the erythrocyte membrane following parasite invasion [126]. Thus, in addition to 
being useful therapeutic leads, these peptide toxins might help validate a new anti-malarial drug target. 
9. Discussion 
In the preceding sections we surveyed a number of spider-venom peptides with potential therapeutic 
applications (Figure 2). With the exception of the MAMPs that have antimicrobial/antifungal activity, 
all of these peptides are stabilized by an inhibitor cystine knot motif. Thus, they are unlikely to suffer 
from  one  of  the  major problems  typically associated with  peptide drugs,  namely rapid  proteolytic 
degradation. As any surviving bite victim will attest, the devastating in vivo efficacy of the 42-residue 
lethal NaV channel toxin from the Australian funnel-web spider [42,127] plainly demonstrates how 
minute quantities of ICK peptides can be effective in humans. Should rapid proteolysis prove to be an 
issue for a spider-venom peptide of therapeutic interest, strategies such as D-amino acid substitution of 
susceptible residues, cyclization to reduce conformational flexibility, and protection of the termini via 
C-terminal amidation or use of N-terminal pyroglutamate could be employed to improve proteolytic 
resistance  [37,128,129].  Indeed,  spiders  routinely  employ  C-terminal  amidation  as  a  protection 
strategy, with ~12% of all known spider toxins containing this posttranslational modification [21]. 
Because of their inherent proteolytic resistance, the plasma half-life of ICK peptides is likely to be 
determined by the rate at which they are cleared by glomerular filtration, which efficiently removes 
small  proteins  and  peptides  that  are  not  bound  to  carrier  proteins  such  as  serum  albumin  [130]. 
However, there are a variety of strategies that can be employed to reduce peptide clearance rates, such 
as increasing the peptide mass by PEGylation, conjugation to carrier proteins, or by making peptides 
more hydrophobic in order to enhance their association with serum albumin; the latter approach can 
also cause hydrophobic depoting, which provides sustained release from a subcutaneous injection [37].  
For  acute  life-threatening  conditions  as  well  as  chronic  conditions  such  as  persistent  pain, 
subcutaneous injection is likely to be an acceptable route of peptide-drug administration. In certain 
pathologies where quality of life is dramatically reduced, intrathecal administration may even be a 
viable option if the difficulties associated with peptide delivery are outweighed by the benefits of 
treatment. Generally, however, oral delivery is likely to be desirable. The intrinsic stability of ICK 
peptides is likely to facilitate the development of oral delivery strategies since they will presumably 
have much longer gut and plasma residence times than typical peptides. Moreover, spider-venom ICK 
peptides  are  small  enough  to  consider  alternative  routes  of  administration  such  as  intranasal, 
transdermal, and pulmonary [131]. Toxins 2010, 2                         
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Figure  2. Spider-venom  peptides  that are serving as  therapeutic leads.  A photo  of the 
spider from which each toxin was isolated is shown, and the name and 3D structure of the 
toxin is indicated at the bottom of each panel. Disulfide bonds are shown as green tubes, 
while  strands and  helices are highlighted in orange and red, respectively. The structure 
of  -CNTX-Pn2a  has  not  yet  been  determined.  Note  that  therapeutic  leads  have  been 
isolated from both ―modern‖ (araneomorph) and ―primitive‖ (mygalomorph) spiders [3]. 
 
An alternative but complementary approach is to develop small-molecule mimetics of spider-venom 
peptides.  The  epitope  (pharmacophore)  that  mediates  the  interaction  of  these  peptides  with  their 
cognate receptors or ion channels can be remarkably small. For example, the interaction between the 
spider-venom  peptide  -hexatoxin-Hv1a  and  invertebrate  CaV  channels  is  mediated  by  a 
pharmacophore comprising only three spatially contiguous residues with a solvent-accessible surface 
area of ~200 Å [132,133], which approximates the typical solvent-accessible surface area of a small 
drug [134]. As long as a high-quality structure of the peptide is available, this enables ab initio design 
of nonpeptide mimetics [135,136], identification of small molecule mimetics via in silico screening of 
chemical libraries, or a combination of these approaches. 
10. Conclusions 
Over a period of more than 300 million years, spiders have evolved an extensive library of bioactive 
peptides. Moreover, in contrast with man-made combinatorial peptide libraries, spider-venom peptides 
have been pre-optimized for high affinity and selectivity against a diverse range of molecular targets. It 
is therefore not surprising that numerous spider-venom peptides have been characterized that potently 
and selectively modulate the activity of a diverse range of therapeutic targets. These include peptides 
that target NaV channels, ASICs, MSCs, and purinergic receptors as well as peptides with antimalarial 
and  antimicrobial  activity.  Most  of  these  peptides  contain  an  ICK  motif,  and  their  extraordinary 
stability provides a variety of delivery options for therapeutic administration. Only a small fraction of Toxins 2010, 2                         
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spider-venom peptides have been characterized, and continued technical advances in the venoms-based 
drug discovery process are likely to uncover many new therapeutic leads from spider venoms. 
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